



IJIRCCCE

e-ISSN: 2320-9801 | p-ISSN: 2320-9798



INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN COMPUTER & COMMUNICATION ENGINEERING

Volume 12, Issue 12, December 2024

ISSN INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIA

Impact Factor: 8.625



9940 572 462



6381 907 438



ijircce@gmail.com



www.ijircce.com



A Review on Prediction of Polycystic Ovary Syndrome(PCOS) for Girl Child using GAI

Pallavi CS, Soumya S

Research Scholar, Srinivas University, Mangalore, India

Assistance Professor, Adichunchanagiri Institute of Technology, Chikkamagaluru, Karnataka, India

Professor, Institute of Computer and Information, Srinivas University, Mangalore, Karnataka, India

ABSTRACT Metabolic syndrome and polycystic ovarian syndrome (PCOS) are common hormonal illnesses that affect many women and frequently result in long-term health issues. Accurate and timely diagnosis is essential for efficient treatment and averting consequences. On the other hand, conventional techniques could be arbitrary and even postpone diagnosis. The potential of artificial intelligence (AI) to transform PCOS detection, classification, and segmentation—as well as its correlation with metabolic syndrome—is examined in this research. We explore how AI might detect important traits linked to both illnesses by using its enormous database of clinical data to learn. The ability of AI to self-correct, which enables ongoing improvements in diagnostic accuracy, is highlighted in the paper. By utilising AI, we hope to improve risk assessments for PCOS and associated problems like metabolic syndrome, make earlier and more accurate diagnoses, and, in the end, create individualised treatment regimens catered to the individual needs of each patient. AI's potential in PCOS and metabolic syndrome is being investigated; this research has the potential to change patient care and health outcomes

KEYWORDS: Artificial Intelligence (AI), Metabolic Syndrome, Polycystic Ovary Syndrome (PCOS)

I. INTRODUCTION

PCOS, or polycystic ovarian syndrome, is the most prevalent gynaecological endocrine illness that has an impact on women's health. It usually affects older, reproductive women. PCOS is characterised by irregular menstrual cycles, infertility, weight gain, skin darkening, hypertension, diabetes, and anomalies or dysfunctions related to metabolism. An unfulfilled ovulation that results in infertility in humans (Escobar-Morreale et al. 2018).

When they are between the ages of 20 and 30, many women receive a PCOS diagnosis. Atypical follicular proliferation in the ovaries is a result of PCOS. Numerous tiny, fluid-filled sacs containing tiny cysts and clusters of pear-sized follicles, each of which contains an immature egg, are located inside the ovaries. Hormonal asymmetry is caused by the cysts. PCOS is a prevalent endocrine-metabolic condition that, according on the diagnostic standards applied, affects 12–18% of women (Teede et al. 2018). The primary clinical symptoms of this condition include polycystic ovarian morphology, hypoovulation, and hirsutism. Metabolic disorders are a major risk factor for patients with PCOS. It was validated by Bhattacharya that Indian women who had PCOS 4.2 time dangerous risk of developing MS compared to those without PCOS. Furthermore, Jamal Hallajzadeh et al.'s metaanalysis of 107 papers revealed a strong correlation. Consequently, PCOS no longer be regarded as a straightforward gynaecological condition. In addition, there is a longer-term risk of type 2 diabetes (T2DM), cardiovascular disease (CVD), and certain malignancies in women with MS (Ntzouvani A et al 2017).

A mixture in the sence of thinking, perception, solving the problem, language comprehension and more. is called artificial intelligence. A general introduction to artificial intelligence opens up a universe of possibilities for the description of machines that emulate nature of human in relation to "cognitive" processes of the human mind, like learning and solve the problem We are currently surrounded by a multitude of artificial intelligence applications. AI is believed to be able to tackle real-world problems with great accuracy and ease. (Jenkins SL et al 2018) AI is currently being used by the healthcare industry to diagnose patients more quickly and accurately than humans. Artificial Intelligence utilised by many academics to automatically classify the ultrasound images. Through clinical practice, AI may "learn" traits from massive amounts of data in order to diagnose diseases. Artificial intelligence (AI) can identify



International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

diseases with high precision and accuracy and can also eliminate unwanted data. This research presents AI applications for PCOS detection, including segmentation and classification of ultrasonic images. AI has demonstrated itself to be the greatest tool for automatically diagnosing PCOS, a disease that requires diagnosis.

II. BACKGROUND

In this part, we give background information and ideas that are pertinent to our work.

A. Factors Affecting PCOS detection

Two medical diseases that often co-occur are metabolic syndrome and polycystic ovarian syndrome (PCOS). You have a much higher chance of developing metabolic syndrome if you have PCOS.




Fig 1: A typical ovary compared to an ovary in a person with PCOS.

B. Metabolic syndrome

Obesity in the centre: This is the buildup of excess fat around the waist and belly.

Your body's cells lose their sensitivity to the hormone insulin, which helps regulate blood sugar levels, and this leads to insulin resistance.

Pressure of High blood is the result of blood consistently pressing against your artery walls.

Insulin resistance or decreased pancreatic insulin production are two possible causes of high blood sugar.

A person with abnormal cholesterol levels will have low HDL ("good") cholesterol and high amounts of triglycerides and LDL ("bad") cholesterol.

C. Polycystic ovarian syndrome

Polycystic ovarian syndrome, or PCOS, is a common condition that significantly affects women who are fertile.

This anomaly affects approximately 1 in 10 men and 1 in 20 women respectively. Many cysts that are filled with fluid grow in the ovaries of most women with PCOS. Unbalances in hormones occur. PCOS manifests as weight gain, irregular menstrual cycles, greasy skin, high blood pressure, diabetes, and irregularities in metabolism. These symptoms indicate that PCOS is still evolving. The cystic forms in the ovaries hold the fluid-filled forms of the immature eggs in check. These cysts are tiny, and pearl-sized clusters are created from them. Androgen produces a lot of male hormones, which contributes to PCOS (Lee et al 2020). These follicles are known as cysts. In a PCOS patient, they are positioned peripherally inside the ovary.

Blood tests, ultrasound scans, and pelvic exams are used to diagnose PCOS and identify any ovarian abnormalities.



International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)




Fig 2. Polycystic Ovarian Syndrome

Fig 2's ultrasound scans illustrate the variations between polycystic and normal follicles in the ovary. Due to the fact that PCOS can be detected via ultrasonography pictures. When a woman is suspected of having PCOS, ovarian ultrasound imaging is essential. An ultrasound scan can be used to between the second and seventh cycle days using a 7MHz transvaginal transducer. The picture should display grayscale coloured data in JPG format, indicating the left and right ovaries, in order to study the scan. The number of follicles and the volume of the ovaries should be included in the detailed report of the images. PCOS and non-PCOS classes are determined by the number, size, location, and reaction of follicles to hormone stimulation

III. METHODOLOGY

A. Ultra Sound Image Segmentation Using AI To Detect PCOS

For PCOS patients to identify their follicles, ultrasound scans are crucial. The health of women is impacted by the longer turnaround time and potential for issues such as intra- and inter-observer discrepancy when follicles are detected manually (Paley et al 2018). Therefore, to improve the identification of follicles from the loaded ovarian pictures, computerised procedures are required. A large number of researchers segmented and preprocessed the ovarian ultrasound pictures in order to determine the extent of PCOS. This section presents some of the studies on the pre-processing and segmentation of ovarian ultrasound images using artificial intelligence approaches to detect PCOS. A method was presented by Palvi Soni et al. wherein an ultrasound image in colour and grayscale was supplied as input.

Fig 3 displays the preprocessed photos used in this investigation




Fig 3. Input image and histogram equalization



International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

B. Metabolic Classification Framework

The metabolic data classification is displayed in Fig. 4. Using a metabolic dataset that was downloaded from the Kaggle repository, the developed framework assesses the use of ten different machine learning classifiers: logistic regression (LR), support vector machine (SVM), K-nearest neighbours (KNNs), decision trees (DTs), random forest (RFs), adaptive boosting (AdaBoost), gradient boosting (GB), stochastic gradient boosting (SGB), categorical boosting (CatBoost), and extreme gradient boosting (XGBoost). The dataset, which has 12,012 entries, includes 29 distinct variables that characterise the condition of different patients. Nonetheless, preprocessing of the data was done to remove missing values (such null values). Furthermore, we observed that the high target class distribution of the metabolic dataset led to imbalanced classes. To ensure that the data classes are balanced, we therefore used the synthetic minority oversampling method (SMOTE) as a data resampling technique.




Fig 4. An overview of the proposed framework for metabolic data classification.

Metabolic Data Collection

Metabolic Information Gathering and Evaluation Over many years, researchers have used a range of machine learning metabolic datasets. In this work, we employ a metabolic dataset as our model. The dataset contains information on various diagnostic techniques, patient demographics, and metabolic syndrome indicators. Table 1 provides a summary of the dataset's characteristics. However, we found that 23.301 of the dataset's 348,348 data samples (data total population) had at least one missing value. However, data preprocessing was used to clear up missing values. We eliminate any data records in this study that have missing values.



International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

Table 1. Metabolic dataset description and analysis.

Metabolic Dataset Description	
Features	Description
Subject ID	Describes the patient's ID.
Subject age	Describes the patient's age.
Gene A	Describes the patient's Gene A in DNA.
Gene B	Describes the patient's Gene B in DNA.
Gene C	Describes the patient's Gene C in DNA.
Gene D	Describes the patient's Gene D in DNA.
Per MCL quantity of blood cells	Describes the patient's blood cells per microliter. The typical range of adults is between 4.35 to 5.65 million blood cells.
Breathing rate	Describes the patient's breathing rate. It is a measurement to check if the patient has breathing difficulty.
Pulse rate	Describes the patient's heart pulse rate.
Diagnostic testing	Describes if the patient has any medical test records.
Carrier testing	Describes if the patient has had any carrier test (a type of genetic test that is used to determine if the patient is a carrier of specific diseases) before.
Enzyme test	Describes if the patient has had any enzyme test (a blood test that measures if the patient has a specific disease) before.
Insulin test	Describes if the patient has any insulin test records.
Thyroid test	Describes if the patient has records of any thyroid tests (a type of blood test that is used to measure thyroid performance).
Gender	Describes the patient's gender (male/female).
Gastrin defect	Describes if the patient has a gastrin hormone defect or not.
Neural anomaly	Describes if the patient has any neural anomaly tests.
Presence of severe allergies	Describes if the patient has any allergies.
Premature delivery	Describes if the patient has any premature delivery record (indicates an early baby birth).
Assistance needed in fertility	Describes if the patient has needed any assistance in fertility.
Previous maternal pregnancy record	Describes if the patient has any previous maternal pregnancy record.
Maternal abortion count	Describes the patient's total number of abortions.
Per MCL quantity of white blood cells	Describes the patient's white blood cells per microliter.
CMP results	Stands for the comprehensive metabolic panel, which is a blood test that provides information about body metabolism.
High triglyceride level	Describes if the patient has high triglyceride.
Reduced HDL	Describes if the patient has a low cholesterol level, which indicates a potential for heart disease.
High BP	Describes if the patient has high blood pressure.
Metabolic syndrome type	Target classes.
Total number of features	28
Total number of records	12,012
Total number of data in population	348,348

A. Dataset

An extensive summary of the datasets used in the PCOS detection methods covered in part is provided in this section. It focuses on the volumes, components, and attributes of the dataset. The dataset used for testing and training is one of the most important components of running detection algorithms. Even though PCOS is a major illness affecting women globally, There isn't much info on PCOS accessible. In this part, there is a table for dataset analysis. This table compares the datasets based on performance and provides a summary of each.

Excellence of the standard dataset

There are several restrictions even though there are a few useful data sets available. For instance, there is a very tiny and undiversified dataset available for PCOS detection. The majority of the datasets are unique creations. Very modest bespoke datasets are available. The quantity of datasets on Kaggle, however, is extremely limited. Because the model can learn and extract features effectively, machine learning performs best with large training and testing datasets. It is



International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

necessary to have a sizable dataset that is neutral towards any one region and broad in viewpoint. To ensure variety, a dataset should also contain women of different ages. The test result won't be correct if the dataset isn't significant and standard.

Imbalanced Dataset

Every class in a balanced dataset has observations of the same types. Although they are not balanced, the current datasets are nonetheless useful. There are a lot of observations in one class and few observations in the other. The outcome is greatly impacted by this trait. As a result, no absolute influence is discovered. A variety of preprocessing methods, such as PCA and SMOTE, can be applied to achieve balance in the dataset

A. PCOS-Related Metabolic Dysfunction

Metabolic syndrome includes the medical characteristics of polycystic ovary syndrome (PCOS), including insulin opposition, obesity, dyslipidemia, and hyperandrogenism. As a result, metabolic syndrome is present in 43% of adult women's and teenage adolescents with PCOS.

B. Obesity in PCOS

One pre-evaluated symptom of PCOS is obesity, particularly abdominal obesity, whose prevalence varies with region and ethnicity. Studies have indicated that a number of PCOS clinical characteristics may be linked to abdominal obesity. For instance, adipocytes secrete non-physiological levels of adipokines, including resistin, leptin, malfunctioning adipose tissue, including adiponectin, retinol binding protein-4 (RBP4), IL6, IL8, TNF- α , and CXC-chemokine ligand 5 (CXCL5), which may be associated with IR.

C. Additional Metabolic Repercussions in PCOS

IR, hyperandrogenism, and dyslipidemia are only a few of the metabolic symptoms that women with PCOS experience. These symptoms are comparable to those of NAFLD and NASH. Furthermore, a significant frequency of NAFLD in women with Polycystic ovary syndrome has been demonstrated by numerous investigations. Furthermore, it is acknowledged raised especially testosterone levels contribute to the development of hepatic steatosis in PCOS-affected girl. Li et al. demonstrated in 2020 that hepatic steatosis in PCOS rats can be brought on by letrozole-induced increased endogenous testosterone.. They also discovered that hyperandrogenism inhibits the AMP-activated protein kinase alpha (AMPKa) signalling, which controls lipid metabolism in HepG2 cells treated with dihydrotestosterone (DHT) and livers treated with letrozole. Furthermore, new research on mitochondrial dysfunction has suggested a connection between NAFLD and PCOS.

Metabolites Involved in the Formation of PCOS

It is inevitable to bring up the gut microbiota while discussing the role of metabolites in PCOS. The human gut is home to around 10^{14} bacteria, mostly from the phyla Firmicutes and Bacteroidetes. Through the use of analytical metabolomics techniques, it has been discovered that these microbes can produce potential metabolites and interact with the reproductive system of humans. Accordingly, a number of studies have shown that individuals with Polycystic ovary syndrome exhibit dysbiosis of the gut microbiota and an aberrant makeup of metabolites, including trimethylamine N-oxide (TMAO), branched-chain amino acids (BCAAs), bile acids (BAs), and short-chain fatty acids (SCFAs). In humans, ceramides can be formed in a range of bodily tissues, and intestinal bacteria can remetabolize BAs, which are derived from cholesterol.

D. Imbalance in Data and Limitations in AI for PCOS and Metabolic Syndrome Detection

Although PCOS and metabolic syndrome can be detected by AI, there are still certain obstacles to overcome. Data imbalance can result in biased models with incorrect diagnoses since data from healthy people frequently dominates data from people with the diseases. Obstacles also include a lack of readily available data, a challenge in comprehending model reasoning, and changing legislation. In order to tackle these issues, scientists are investigating methods for augmenting data, employing suitable assessment criteria, and creating comprehensible models. In order to guarantee that ethical standards are fulfilled and the technology helps patients as well as healthcare systems, cooperation between AI experts, medical practitioners, and patients is essential. While generating AI models for PCOS and metabolic syndrome detection is hampered by data imbalance, Generative Adversarial Networks (GANs) present a viable remedy. GANs have the potential to produce synthetic data, which overcomes the constraints of real-world data



International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

availability, in contrast to conventional techniques that handle imbalanced data by oversampling or undersampling. Consider a situation in which a GAN is created expressly to identify PCOS. Real-world data, such as patient characteristics and ultrasound images of the ovaries, might be analysed by this GAN. After the GAN learns the underlying patterns, it might produce artificial photos that closely mimic real-world PCOS cases. By doing this, the training dataset would be effectively increased, which would enhance the model's capacity to detect PCOS in actual patients—particularly when real-world data is limited. Let z be the random vector and x be a TS window from the dataset distribution p_X , mathematically speaking. We just take into account the fact that z comes from a uniform distribution with a $[-1,1]$ support. Taking z as input, the generative model produces TS data, $G(z)$, also has similar support as x . Let G and D be the generating and discriminative models. Write p_G to represent the distribution of $G(z)$. Approximating the likelihood that the input TS data is taken from p_X is the goal of the discriminative model. If $x \sim p_X$, then $d(x)=1$, and if $x \sim p_G$, then $D(x)=0$. Together, the discriminative and generative models can be trained by resolving.

$$\min_G \max_D V(D, G) = E_{x \sim p_{real}(x)} [\log D(x)] + E_{z \sim p_z(z)} [\log(1 - D(G(x)))] \quad (1)$$

The generator used in the first dataset has five levels. Input layer corresponds to latent vector z , which consists of thirty-two elements. A fully-connected layer with 256 nodes comes next, followed by three more fully-connected layers with 512, 1024, and 699 nodes in order of precedence. Batch normalisation is applied and a Leaky ReLU activation function is fitted to each layer. The final layer is then moulded into a 3×233 node structure to fit the incoming data's architecture. In contrast, the discriminator receives input that is either synthetic or real and is first moulded into a fully linked layer with 899 nodes. After that, this layer goes through two more fully-connected layers with 512 and 256 nodes, respectively, each batch normalisation and leaky ReLU activation functions. Output node is single node that uses a Sigmoid activation function to determine if the data is synthetic or real (Deng, N. et al. (2023)).

E. Convolutional neural network (CNN)

For image analysis, convolutional neural networks, or CNNs, are a useful tool., which makes them perfect for applications such as the identification of PCOS from ultrasound scans. CNNs have demonstrated great accuracy in PCOS detection and can automatically extract pertinent features from the data, doing away with the requirement for human feature engineering. Furthermore, pre-trained CNNs can be modified to perform better and save time for particular applications like PCOS detection. On the other hand, issues like generalizability, interpretability, and data availability must be resolved. Subsequent investigations will concentrate on surmounting data constraints, creating comprehensible models, and verifying CNNs for clinical application in the identification of metabolic syndrome and PCOS. (Kwapisz et al., 2011).

RNNs: Have the ability to analyse sequential data, such as video frames, with high accuracy in order to detect movement patterns and forecast future developments.

CNNs: Frequently attain remarkable precision in identifying essential characteristics from pictures or videos allowing impartial evaluation.

Although GANs have distinct benefits in terms of data creation, personalisation, and understandable feedback, they might not necessarily be more accurate than other well-trained algorithms in all areas of PCOS and Metabolic syndrome detection. Often, the optimum strategy combines several algorithms to take advantage of each one's unique advantages and produce the greatest possible outcomes.

To address the constraints in PCOS and Metabolic syndrome detection studies, this study tell us with the help of Generative Adversarial Networks to create synthetic data. GANs have the potential to help AI models analyse varied patterns, forecast diagnostic outcomes, and even personalise interventions by supplementing limited and imbalanced datasets. While data normalisation improves the acceptability of generated data for GAN training, using class-specific GANs and zero-padding approaches ensures compatibility with deep learning algorithms. This opens the door to more personalised PCOS and Metabolic syndrome detection models and higher diagnosis accuracy, perhaps leading to better patient outcomes. However, ethical constraints, generalizability of synthetic data to real-world circumstances, and overall quality of the generated data continue to be persistent obstacles in increasing PCOS and Metabolic syndrome detection diagnosis through data augmentation Model introduces a novel training strategy for both generator and encoder components. In contrast to traditional approaches that tightly couple these components with the



International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

discriminator, model takes more relaxed approach. This relaxation allows the generator and encoder to continue training until they can produce a new set of data samples that closely resemble the true distribution of the original data (Hampel, F. R et al. (2022)).

Moreover, our proposed model presents a fresh conceptual framework for the trained encoder-discriminator duo. This framework can be effectively utilized as a one-class binary classifier. Instead of rigidly categorizing data into two distinct classes, our model's encoder-discriminator combination excels at discerning the unique characteristics of a single class. This makes it particularly suitable for anomaly detection and classification tasks where the focus is on identifying deviations from the norm rather than distinguishing between multiple classes.

This study aims to investigate and understand a specific subject or problem. It involves a systematic examination of relevant data, literature, or phenomena, with the goal of generating insights, making discoveries, or testing hypotheses.(Wang et al (2023)) The proposed methodology for developing a novel cloud computing system for PCOS and Metabolic syndrome detection using generative artificial intelligence (AI) techniques comprises several key steps.

First, the process begins with the collection and preprocessing of data. This involves gathering historical data on PCOS and Metabolic syndrome, resolution, sensitivity, and other relevant factors. Additionally, real-time data is integrated through sensors, image sensors, and measurements. Data quality is ensured by addressing missing values, outliers, and performing necessary normalization. Remote sensing data, including satellite imagery, are also explored for their potential in improving predictions.

Next, a robust cloud computing infrastructure is established to support the system's scalability and accessibility. This infrastructure includes setting up data storage solutions and implementing stringent data security measures.

This generative model is trained using historical data and is carefully fine-tuned for optimal performance. Special attention is given to maintaining meaningful semantic relationships among the features in the generated data. Real-time data integration is a critical aspect, with the cloud-based system continuously updated with data from sensors and other sources. Periodic retraining of prediction models ensures they adapt to changing conditions. Data streaming and event-driven architecture are employed for seamless real-time updates.

To make the system user-friendly, a web or mobile application is developed, providing farmers and stakeholders with access to PCOS and Metabolic syndrome detection. Data is presented through interactive charts, maps, and dashboards for effective visualization.

Scalability and performance optimization are achieved by ensuring the system can handle increased data volumes and user loads. Cloud resources are optimized, and auto-scaling mechanisms are implemented to manage varying workloads effectively.

Regular model evaluation and feedback collection from users are conducted to improve prediction accuracy and system capabilities. Security measures are maintained to protect data and user privacy, adhering to relevant regulations and standards.

Standard training strategy not be suitable for numerous application scenarios. Often, maintain semantic relation within the feature sets in the information formed by the generator is crucial. The data set used for the discriminator differs from generated by the generator, leading to training instability, characterized by fluctuating generator loss

IV. CONCLUSION

The collecting of extensive data via wearable sensors is critical. Similar to creating realistic and diverse datasets is critical for developing effective models that assess patients' PCOS and Metabolic syndrome. The future conductors of PCOS and Metabolic syndrome detection diagnosis are algorithms and Generative Adversarial Networks (GANs), which work together to create personalised care symphonies.



International Journal of Innovative Research in Computer and Communication Engineering (IJIRCCCE)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

These technological innovations benefit both individuals and healthcare professionals by enabling data-driven assessments, early intervention, personalised treatment methods, remote monitoring, and ongoing research and development. This collaborative duet between algorithms and GANs is a beacon of hope for those living with PCOS and Metabolic syndrome, with each diagnostic path resonating as a distinct and victorious tune.

REFERENCES

1. IF. Stein, ML. Leventhal, Amenorrhea associated with bilateral polycystic ovaries, *Am. J. Obstet. Gynecol.* 29 (2) (1935) 181–191.
2. AH. Balen, GS. Conway, G. Kaltsas, K. Techatrasak, PJ. Manning, C. West, et al., Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients, *Hum Reprod.* 10 (8) (1995) 2107–2111.
3. C. Farquhar, Introduction and history of polycystic ovary syndrome, in: GT Kovacs, R Norman (Eds.), *Polycystic Ovary Syndrome* [Internet], second ed., Cambridge University Press, 2001, pp. 4–24, Available from: https://www.cambridge.org/core/product/identifier/CBO9780511545191A008/type/book_part [cited 2022 Oct 31]
4. R. Hart, M. Hickey, S. Franks, Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome, *Best Pract. Res. Clin. Obstet. Gynaecol.* 18(5) (2004) 671–683.
5. SM. Sirmans, KA. Pate, Epidemiology, diagnosis, and management of polycystic ovary syndrome, *Clin. Epidemiol.* 6 (2013) 1–13.
6. H. Teede, A. Deeks, L. Moran, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan, *BMC Med.* 8 (1) (2010) 41.
7. M. Brassard, Y. AinMelk, JP. Baillargeon, Basic infertility including polycystic ovary syndrome, *Med. Clin. N. Am.* 92 (5) (2008) 1163–1192, xi.
8. CJ. Glueck, H. Phillips, D. Cameron, L. Sieve-Smith, P. Wang, Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study, *Fertil. Steril.* 75 (1) (2001) 46–52.
9. DJ. Jakubowicz, MJ. Iuorno, S. Jakubowicz, KA. Roberts, JE. Nestler, Effects of metformin on early pregnancy loss in the polycystic ovary syndrome, *J. Clin. Endocrinol. Metab.* 87 (2) (2002) 524–529.
10. ME. Lujan, BY. Jarrett, ED. Brooks, JK. Reines, AK. Peppin, N. Muhn, et al., Updated ultrasound criteria for polycystic ovary syndrome: reliable threshold elevated follicle population and ovarian volume, *Hum. Reprod.* 28 (5) (2013) 1361–1368.
11. D. Dewailly, H. Gronier, E. Poncelet, G. Robin, M. Leroy, P. Pigny, et al., Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries, *Hum. Reprod.* 26 (11) (2011) 3123–3129.
12. MC. Allem, IS. Tummon, JL. Phy, SC. Foong, DA. Dumesic, DR. Session, Diagnosis of polycystic ovaries by three-dimensional transvaginal ultrasound, *Fertil. Steril.* 85 (1) (2006) 214–219.
13. R. Azziz, KS. Woods, R. Reyna, TJ. Key, ES. Knochenhauer, BO. Yildiz, The prevalence and features of the polycystic ovary syndrome in an unselected population, *J. Clin. Endocrinol. Metab.* 89 (6) (2004) 2745–2749.
14. LC. Morley, TMH. Tang, AH. Balen, Metformin therapy for the management of infertility in women with polycystic ovary syndrome, *BJOG: Int. J. Obstet. Gynaecol.* 124 (12) (2017) e306–e313.
15. BH. Al Wattar, M. Fisher, L. Bevington, V. Talaulikar, M. Davies, G. Conway, et al., Clinical practice guidelines on the diagnosis and management of polycystic ovary syndrome: A systematic review and quality assessment study, *J. Clin. Endocrinol. Metab.* 106 (8) (2021) 2436–2446. Badawy, A. Elnashar, Treatment options for polycystic ovary syndrome, *Int. J. Womens Health.* 3 (2011) 25–35. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome, *Obstet. Gynecol.* 114 (4) (2009) 936.
17. R. Azziz, E. Carmina, Z. Chen, A. Dunaif, JSE. Laven, RS. Legro, et al., Polycystic ovary syndrome, *Nat. Rev. Dis. Primers* 2 (2016) 16057.
18. RJ. Norman, D. Dewailly, RS. Legro, TE. Hickey, Polycystic ovary syndrome, *Lancet* 370 (9588) (2007) 685–697. Health Navigator New Zealand, Polycystic ovary syndrome (huahua huakua) | Health Navigator NZ [Internet], Health Navig. N. Z. (2022) Available from:



INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIA



INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN COMPUTER & COMMUNICATION ENGINEERING

 9940 572 462  6381 907 438  ijircce@gmail.com



www.ijircce.com

Scan to save the contact details